BBOT
BridgeBio Oncology Therapeutics, Inc.11.85
-0.15-1.25%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
947.87MP/E (TTM)
-Basic EPS (TTM)
-1.45Dividend Yield
0%Recent Filings
10-K
FY2025 results
BridgeBio Oncology Therapeutics posted FY2025 net loss of $134M, up 81% y/y from $74M, driven by $121M R&D spend (66% y/y rise) as Phase 1 trials for KRAS inhibitors BBO-8520/BBO-11818 and PI3Kα breaker BBO-10203 ramped with Q4 data readouts showing 65% ORR for BBO-8520 in KRAS G12C NSCLC and clean safety. Q4 momentum built on encouraging early efficacy—BBO-8520 combo with pembro drove tumor reductions across lines; BBO-10203 hit full target engagement sans hyperglycemia; BBO-11818 notched PDAC PR—setting up H1/H2 2026 updates while cash swelled to $426M post de-SPAC. Debt-free with $374M cash equivalents. Clinical trials may fail.
8-K
BBOT 2025 results, pipeline data
BridgeBio Oncology Therapeutics reported 2025 net loss of $134M, up from $74M, with R&D expenses climbing to $121M amid clinical advances; cash hit $425.5M, funding ops into 2028. Encouraging Phase 1 data showed BBO-8520's 65% ORR in KRASG12C NSCLC and BBO-11818's first panKRAS PR in PDAC. Data readouts loom H2 2026. Cash sustains combos.
8-K
Strong early oncology data
BridgeBio Oncology Therapeutics unveiled promising early clinical data on January 7, 2026, for its RAS and PI3Kα pipeline. BBO-8520 monotherapy hit 65% ORR and 66% 6-month PFS in KRAS G12C NSCLC, with durable responses and clean safety. BBO-11818 scored a PR in pancreatic cancer; BBO-10203 showed no hyperglycemia. Data validates combo potential. Updates due H2 2026.
10-Q
Q3 FY2025 results
BridgeBio Oncology Therapeutics ramped up R&D spending 96% y/y to $35.1M in Q3 ended September 30, 2025, driving a $44.8M net loss, up from $17.3M last year, while G&A jumped on a $7.8M nonreciprocal stock grant to related-party BridgeBio Pharma and a $3.0M de-SPAC executive bonus. Cash swelled to $468.3M after August's reverse recap with Helix and $260.9M PIPE, funding runway into 2028; operating cash burn hit $71.7M YTD (derived). Closed de-SPAC August 11 for $373.5M net proceeds (cash/trust account), no goodwill recognized. Shares exploded from 11K to 79.2M on conversion, slashing diluted EPS loss to $(1.03) from $(1,562). Clinical trials advance smoothly. Pipeline success hinges on Phase 1 data.
8-K
Q3 loss widens; cash to 2028
BridgeBio Oncology Therapeutics reported Q3 2025 net loss of $44.8 million, up from $17.3 million year-over-year, driven by ramped R&D at $35.1 million and G&A at $14.1 million post-SPAC debut. Cash stands at $468.3 million, funding operations into 2028. Three Phase 1 trials advance; data due 2026. New CFO joined.
BBIO
BridgeBio Pharma, Inc.
75.69+1.18
BDTX
Black Diamond Therapeutics, Inc
2.62-0.03
BOLD
Boundless Bio, Inc.
1.14+0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CRDF
Cardiff Oncology, Inc.
2.40-0.01
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
KURA
Kura Oncology, Inc.
10.63+0.07
NUVB
Nuvation Bio Inc.
8.66+0.15
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
TNGX
Tango Therapeutics, Inc.
8.96-0.16